¼¼°èÀÇ ±¸³»¿° Ä¡·áÁ¦ ½ÃÀå : ½ÃÀå ±Ô¸ð ºÐ¼®(¾à¹° Á¾·ùº°, Á¦Çüº°, Áö¿ªº°) ¹× ¿¹Ãø(2022-2032³â)
Global Mouth Ulcer Treatment Market Size study, by Drug Class (Antimicrobial, Antihistamine, Analgesics & Corticosteroids), by Formulation (Gels, Lozenges), and Regional Forecasts 2022-2032
»óǰÄÚµå
:
1735706
¸®¼Ä¡»ç
:
Bizwit Research & Consulting LLP
¹ßÇàÀÏ
:
2025³â 05¿ù
ÆäÀÌÁö Á¤º¸
:
¿µ¹® 285 Pages
¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.
¼¼°è ±¸³»¿° Ä¡·áÁ¦ ½ÃÀåÀº 2023³â ¾à 15¾ï 8,000¸¸ ´Þ·¯·Î Æò°¡µÇ¸ç, 2024-2032³â ¿¹Ãø ±â°£ µ¿¾È 3.90%ÀÇ ¾ÈÁ¤ÀûÀÎ CAGR·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ±¸³»¿°Àº Ä¡¸íÀûÀÌÁö´Â ¾ÊÁö¸¸ °¡Àå ÈçÇÑ ±¸° À§»ý ¹®Á¦ Áß ÇϳªÀ̸ç, ÅëÁõ°ú À½½Ä¹° ¼·Ãë ¹× ´ëÈ ¾î·Á¿òÀ¸·Î ÀÎÇØ »îÀÇ Áú¿¡ Å« ¿µÇâÀ» ¹ÌĨ´Ï´Ù. µµ½Ã »ýȰ¾ç½ÄÀÌ ÁøÈÇÏ°í ½ºÆ®·¹½º¿Í °ü·ÃµÈ °Ç° »óŰ¡ Áõ°¡ÇÔ¿¡ µû¶ó Àç¹ß¼º ¾ÆÇÁŸ¼º ±¸³»¿°°ú ¿Ü»óÀ¸·Î ÀÎÇÑ ±¸° ±Ë¾çÀÇ ¹ß»ý·üÀº Àü ¼¼°èÀûÀ¸·Î Áö¼ÓÀûÀ¸·Î Áõ°¡Çϰí ÀÖÀ¸¸ç, È¿°úÀûÀÎ Ä¡·á ¼Ö·ç¼Ç¿¡ ´ëÇÑ Çʿ伺ÀÌ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ±× °á°ú, ½ÃÀåÀº Á¦³×¸¯ ÀϹÝÀǾàǰ ÁøÅëÁ¦¿¡¼ ÄÚ¸£Æ¼ÄÚ½ºÅ×·ÎÀÌµå ±â¹Ý Á©, ¼Òµ¶¿ë ·Î¼Ç µî º¸´Ù Áøº¸µÈ Ç¥Àû Ä¡·áÁ¦·Î À̵¿Çϰí ÀÖ½À´Ï´Ù.
ÀÇ·á ±â¾÷µéÀº Á¡¸· Á¢Âø·ÂÀ» °³¼±Çϰí Áõ»óÀ» Àå±â°£ ¿ÏÈÇÏ´Â Çõ½ÅÀûÀÎ ¾à¹° Á¦Á¦ ¹× Àü´Þ ¸ÞÄ¿´ÏÁò¿¡ ÅõÀÚÇϰí ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, ¼ÓÈ¿¼º°ú ¼¹æ¼ºÀ» °âºñÇÑ Á©ÀÇ °³¹ß·Î Ä¡·áÀÇ ¹ÐÂø¼ºÀÌ Çâ»óµÇ°í Ä¡À¯°¡ »¡¶óÁ³½À´Ï´Ù. ¶ÇÇÑ, ²Ü, ¾Ë·Î¿¡º£¶ó, °¨ÃÊ¿Í °°Àº õ¿¬ ¼ººÐÀ» ±¹¼Ò Ä¡·áÁ¦¿¡ µµÀÔÇÏ¿© Àüü·ÐÀûÀÎ ¼±ÅÃÀ» ¿øÇÏ´Â ¼ÒºñÀڵ鿡°Ô ¾îÇÊÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¹ßÀüÀÌ ½ÃÀå È®´ë¸¦ ÃËÁøÇÏ´Â ÇÑÆí, Á¶±â Ä¡·áÀÇ º¸±ÞÀ» ÃËÁøÇÏ´Â µ¥ ÀÖ¾î Áß¿äÇÑ ¿ä¼Ò´Â ¿©ÀüÈ÷ Àνİú ±³À°ÀÔ´Ï´Ù. µðÁöÅÐ Ç÷§Æû°ú ¿ø°Ý Ä¡°ú Áø·áµµ ÀÌ·¯ÇÑ Ãß¼¼¿¡ ±â¿©Çϰí ÀÖÀ¸¸ç, Ä¡°ú¸¦ ¹æ¹®ÇÏÁö ¾Ê°íµµ Áø·á¿Í Á¦Ç° ¼±Åÿ¡ Á¢±ÙÇÒ ¼ö ÀÖ´Â ±âȸ¸¦ Á¦°øÇϰí ÀÖ½À´Ï´Ù.
ÀÌ·¯ÇÑ ¾àÁø¿¡µµ ºÒ±¸Çϰí, ½ÃÀå¿¡´Â ¸î °¡Áö Àå¾Ö¹°ÀÌ ÀÖ½À´Ï´Ù. ¼ÒºñÀÚ ÃëÇâÀÇ ´Ù¾ç¼º, Áö¿ª¿¡ µû¶ó¼´Â °í°¡ÀÇ Ä¡·áºñ, ¼Ò¾Æ ¹× ³ë¾àÀÚ Àü¿ë Á¦Á¦ÀÇ ºÎÁ· µîÀÌ º»°ÝÀûÀÎ ½ÃÀå ħÅõ¿¡ °É¸²µ¹ÀÌ µÇ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ±Ë¾çÀÇ Àç¹ßÀº Á¾Á¾ À§ÀåÀå¾Ö³ª ¸é¿ªºÎÀü°ú °°Àº ±Ùº»ÀûÀÎ Àü½ÅÁúȯÀÇ Â¡ÈÄÀÎ °æ¿ì°¡ ¸¹±â ¶§¹®¿¡ ´Üµ¶ Ä¡·áÁ¦°¡ ¾Æ´Ñ Á¾ÇÕÀûÀÎ ÀÇ·á Àü·«ÀÌ ÇÊ¿äÇÕ´Ï´Ù. ±×·¯³ª ÀǾàǰ ¿¬±¸°³¹ßÀº Ç׿°Áõ ÀÛ¿ë°ú Ç×±Õ ÀÛ¿ëÀ» °âºñÇÑ ÀÌÁß ÀÛ¿ë Á¦Á¦¿¡ ÃÊÁ¡À» ¸ÂÃß°í ÀÖÀ¸¸ç, ÀÌ´Â Ä¡·áÀÇ ÆÐ·¯´ÙÀÓÀ» ÀçÁ¤ÀÇÇÒ ¼ö ÀÖ´Â °¡´É¼ºÀ» °¡Áö°í ÀÖ½À´Ï´Ù.
¶ÇÇÑ, Á¦¾à»çµéÀº ó¹æÀüÀÌ ÇÊ¿äÇÑ °·ÂÇÑ Á¦Çü°ú ¼ÒºñÀÚ°¡ ½±°Ô ±¸ÇÒ ¼ö ÀÖ´Â OTC Á¦Ç° ¸ðµÎ¸¦ Áß½ÃÇÏ´Â ÇÏÀ̺긮µå ¸ðµ¨¿¡µµ °ü½ÉÀ» ±â¿ïÀ̰í ÀÖ½À´Ï´Ù. ¸¶ÃëÁ¦³ª Ä¡·áÁ¦¸¦ ÇÔÀ¯ÇÑ °¡±ÛÀÇ ÀαⰡ ³ô¾ÆÁö°í ÀÖ´Â °ÍÀº ÀÌ·¯ÇÑ Àü¹®Àû È¿À²¼º°ú ÀÚ°¡Åõ¿©ÀÇ Æí¸®ÇÔÀ» °áÇÕÇÏ´Â °ÍÀ» ¹Ý¿µÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, »õ·Î¿î ÄÚ¸£Æ¼ÄÚ½ºÅ×·ÎÀ̵å À¯µµÃ¼¿Í ¹æºÎÁ¦ÀÇ Á¡¸· Åõ¿© Á¦Á¦¸¦ Æò°¡ÇÏ´Â ÀÓ»ó½ÃÇèÀÌ ÁøÇà ÁßÀ̸ç, ÀÌ´Â ´ÙÀ½ ´Ü°èÀÇ Ä¡·á Çõ½ÅÀÌ ÀÌ·ç¾îÁú °ÍÀÓÀ» ½Ã»çÇÕ´Ï´Ù. °Ç°À» Áß½ÃÇÏ´Â ¼ÒºñÀÚµéÀº ¼³ÅÁ°ú ¹æºÎÁ¦¸¦ »ç¿ëÇÏÁö ¾Ê´Â ·ÎÁ¨Áö¿Í Á©À» ã´Â Ãß¼¼¿¡µµ ¿µÇâÀ» ¹ÌÄ¡°í ÀÖ½À´Ï´Ù.
Áö¿ªÀûÀ¸·Î ºÏ¹Ì´Â źźÇÑ ÀÇ·á ÀÎÇÁ¶ó, ±¸° À§»ý¿¡ ´ëÇÑ ³ôÀº ÀνÄ, ÷´Ü ±¹¼Ò Á¦Á¦ÀÇ º¸±ÞÀ¸·Î ¾ÐµµÀûÀÎ ½ÃÀå Á¡À¯À²À» Â÷ÁöÇϰí ÀÖ½À´Ï´Ù. À¯·´Àº ¿µ±¹, µ¶ÀÏ, ÇÁ¶û½º µîÀÇ ±¹°¡¿¡¼ µÎµå·¯Áø ¼ö¿ä¸¦ º¸À̰í ÀÖÀ¸¸ç, ±¸° °ü¸®ÀÇ ±â¼ú Çõ½Å°ú º¸Çè ó¹æ Ä¡·á°¡ °·ÂÇÑ ½ÃÀå »ýŰ踦 Çü¼ºÇϰí ÀÖ½À´Ï´Ù. ÇÑÆí, ¾Æ½Ã¾ÆÅÂÆò¾çÀº Àα¸ ¹Ðµµ Áõ°¡, Ä¡°ú Ä¡·á Á¢±Ù¼º Çâ»ó, Àεµ, Áß±¹, Çѱ¹ µîÀÇ ±¹°¡¿¡¼ ¼Ò¸Å ¾à±¹ ³×Æ®¿öÅ© È®´ë¿¡ ÈûÀÔ¾î ±Þ¼ºÀåÇÏ´Â Áö¿ªÀ¸·Î ºÎ»óÇϰí ÀÖ½À´Ï´Ù. ¶óƾ¾Æ¸Þ¸®Ä«¿Í Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«µµ ÀÇ·áºñ ÁöÃâ Áõ°¡¿Í Á¤ºÎ ¹× ºñÁ¤ºÎ±â±¸ÀÇ ±¸°º¸°Ç Ä·ÆäÀο¡ ÈûÀÔ¾î Å« ±â¿©¸¦ ÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
¸ñÂ÷
Á¦1Àå ¼¼°èÀÇ ±¸³»¿° Ä¡·áÁ¦ ½ÃÀå : ÁÖ¿ä ¿ä¾à
- ¼¼°èÀÇ ±¸³»¿° Ä¡·áÁ¦ ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø(2022-2032³â)
- Áö¿ªº° °³¿ä
- ºÎ¹®º° °³¿ä
- ÁÖ¿ä µ¿Çâ
- °æ±âÈÄÅðÀÇ ¿µÇâ
- ¾Ö³Î¸®½ºÆ®ÀÇ Á¦¾È°ú °á·Ð
Á¦2Àå ¼¼°èÀÇ ±¸³»¿° Ä¡·áÁ¦ ½ÃÀå : Á¤ÀÇ¿Í ºÐ¼® °¡Á¤
- ºÐ¼® ¸ñÀû
- ½ÃÀå Á¤ÀÇ
- ºÐ¼® °¡Á¤
- Æ÷ÇÔ°ú Á¦¿Ü
- Á¦ÇÑ»çÇ×
- °ø±ÞÃø ºÐ¼®
- °¡¿ë¼º
- ÀÎÇÁ¶ó
- ±ÔÁ¦ ÇÁ·¹ÀÓ¿öÅ©
- ½ÃÀå °æÀï
- °æÁ¦¼º(¼ÒºñÀÚÀÇ °üÁ¡)
- ¼ö¿äÃø ºÐ¼®
- ±ÔÁ¦ ÇÁ·¹ÀÓ¿öÅ©
- ±â¼ú Áøº¸
- ģȯ°æ
- ¼ÒºñÀÚ Àǽİú ¼ö¿ë
- ºÐ¼® ¹æ¹ý
- ºÐ¼® ´ë»ó ±â°£
- ÅëÈ È¯»êÀ²
Á¦3Àå ¼¼°èÀÇ ±¸³»¿° Ä¡·áÁ¦ ½ÃÀå ¿ªÇÐ
- ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
- ½ÃÀåÀÌ ÇØ°áÇØ¾ß ÇÒ °úÁ¦
- ½ÃÀå ±âȸ
Á¦4Àå ¼¼°èÀÇ ±¸³»¿° Ä¡·áÁ¦ ½ÃÀå : »ê¾÷ ºÐ¼®
- Porter's Five Forces ¸ðµ¨
- °ø±Þ ±â¾÷ÀÇ ±³¼··Â
- ±¸¸ÅÀÚÀÇ ±³¼··Â
- ½Å±Ô Âü¿©¾÷üÀÇ À§Çù
- ´ëüǰÀÇ À§Çù
- °æÀï ±â¾÷ °£ÀÇ °æÀï °ü°è
- Porter's Five Forces ¸ðµ¨·ÎÀÇ ÇâÈÄ Á¢±Ù¹ý
- Porter's Five ForcesÀÇ ¿µÇ⠺м®
- PESTEL ºÐ¼®
- Á¤Ä¡Àû ¿äÀÎ
- °æÁ¦Àû ¿äÀÎ
- »çȸÀû ¿äÀÎ
- ±â¼úÀû ¿äÀÎ
- ȯ°æÀû ¿äÀÎ
- ¹ýÀû ¿äÀÎ
- ÁÖ¿ä ÅõÀÚ ±âȸ
- ÁÖ¿ä ¼º°ø Àü·«
- µð½º·´¼Ç µ¿Çâ
- ¾÷°è Àü¹®°¡ÀÇ °üÁ¡
- ¾Ö³Î¸®½ºÆ®ÀÇ Á¦¾È°ú °á·Ð
Á¦5Àå ¼¼°èÀÇ ±¸³»¿° Ä¡·áÁ¦ ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø : ¾à¹° Á¾·ùº°(2022-2032³â)
- ºÎ¹® ´ë½Ãº¸µå
- ¼¼°è ½ÃÀå : Ç×±ÕÁ¦ ¸ÅÃâ µ¿Çâ(2022³â¡¤3032³â)
- ¼¼°è ½ÃÀå : Ç×È÷½ºÅ¸¹ÎÁ¦ ¸ÅÃâ µ¿Çâ(2022³â¡¤3032³â)
- ¼¼°è ½ÃÀå : ÁøÅëÁ¦ ¹× ÄÚ¸£Æ¼ÄÚ½ºÅ×·ÎÀÌµå ¸ÅÃâ µ¿Çâ(2022³â¡¤3032³â)
Á¦6Àå ¼¼°èÀÇ ±¸³»¿° Ä¡·áÁ¦ ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø : Á¦Çüº°(2022-2032³â)
- ºÎ¹® ´ë½Ãº¸µå
- ¼¼°è ½ÃÀå : °Ö ¸ÅÃâ µ¿Çâ(2022³â¡¤3032³â)
- ¼¼°è ½ÃÀå : ·ÎÁ¨Áö ¸ÅÃâ µ¿Çâ(2022³â¡¤3032³â)
Á¦7Àå ¼¼°èÀÇ ±¸³»¿° Ä¡·áÁ¦ ½ÃÀå ±Ô¸ð¿Í ¿¹Ãø : Áö¿ªº°(2022-2032³â)
- ºÏ¹Ì ½ÃÀå
- À¯·´ ½ÃÀå
- ¿µ±¹ ½ÃÀå
- µ¶ÀÏ ½ÃÀå
- ÇÁ¶û½º ½ÃÀå
- ½ºÆäÀÎ ½ÃÀå
- ÀÌÅ»¸®¾Æ ½ÃÀå
- ±âŸ À¯·´ ½ÃÀå
- ¾Æ½Ã¾ÆÅÂÆò¾ç ½ÃÀå
- Áß±¹ ½ÃÀå
- Àεµ ½ÃÀå
- ÀϺ» ½ÃÀå
- È£ÁÖ ½ÃÀå
- Çѱ¹ ½ÃÀå
- ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç ½ÃÀå
- ¶óƾ¾Æ¸Þ¸®Ä« ½ÃÀå
- ºê¶óÁú ½ÃÀå
- ¸ß½ÃÄÚ ½ÃÀå
- ±âŸ ¶óƾ¾Æ¸Þ¸®Ä« ½ÃÀå
- Áßµ¿ ¹× ¾ÆÇÁ¸®Ä« ½ÃÀå
- »ç¿ìµð¾Æ¶óºñ¾Æ ½ÃÀå
- ³²¾ÆÇÁ¸®Ä«°øÈ±¹ ½ÃÀå
- ±âŸ Áßµ¿ ¹× ¾ÆÇÁ¸®Ä« ½ÃÀå
Á¦8Àå °æÀï Á¤º¸
- ÁÖ¿ä ±â¾÷ SWOT ºÐ¼®
- GlaxoSmithKline plc
- Sun Pharmaceutical Industries Ltd.
- Colgate-Palmolive Company
- ÁÖ¿ä ½ÃÀå Àü·«
- ±â¾÷ °³¿ä
- GlaxoSmithKline plc
- ÁÖ¿ä Á¤º¸
- °³¿ä
- À繫(µ¥ÀÌÅÍ °¡¿ë¼º¿¡ µû¶ó ´Ù¸§)
- Á¦Ç° °³¿ä
- ½ÃÀå Àü·«
- Sun Pharmaceutical Industries Ltd.
- Colgate-Palmolive Company
- Pfizer Inc.
- 3M Company
- Bristol-Myers Squibb Company
- Reckitt Benckiser Group plc
- Church & Dwight Co., Inc.
- Bausch Health Companies Inc.
- ECR Pharmaceuticals
- Taro Pharmaceutical Industries Ltd.
- BLIS Technologies Ltd.
- Sinclair Pharma
- Prestige Consumer Healthcare Inc.
- Reddy's Laboratories Ltd.
Á¦9Àå ºÐ¼® ÇÁ·Î¼¼½º
- ºÐ¼® ÇÁ·Î¼¼½º
- µ¥ÀÌÅÍ ¸¶ÀÌ´×
- ºÐ¼®
- ½ÃÀå ¿¹Ãø
- °ËÁõ
- °£Çà
- ºÐ¼® ¼Ó¼º
ksm
¿µ¹® ¸ñÂ÷
The Global Mouth Ulcer Treatment Market is valued at approximately USD 1.58 billion in 2023 and is projected to grow at a steady CAGR of 3.90% over the forecast period 2024-2032. Mouth ulcers, though non-lethal, are among the most common oral health problems, significantly affecting quality of life due to pain and difficulty in eating, drinking, and speaking. As urban lifestyles evolve and stress-related health conditions rise, the incidence of recurrent aphthous stomatitis and trauma-induced oral ulcers continues to increase globally, driving the need for effective treatment solutions. The market has consequently experienced a shift from generic over-the-counter pain relievers to more advanced, target-specific therapeutics such as corticosteroid-based gels and antiseptic lozenges.
Healthcare companies are investing in innovative drug formulations and delivery mechanisms that improve mucosal adhesion and offer prolonged symptom relief. For instance, the development of gels with rapid onset and sustained release properties has allowed better treatment adherence and faster healing outcomes. Additionally, the incorporation of natural ingredients like honey, aloe vera, and licorice in topical treatments appeals to consumers seeking holistic alternatives. While these advancements foster market expansion, awareness and education remain key components in enhancing early treatment uptake. Digital platforms and tele-dentistry have also started contributing to this momentum, empowering users with access to consultations and product choices without clinical visits.
Despite these strides, the market encounters several roadblocks. Variability in consumer preferences, high treatment costs in some regions, and a lack of specialized formulations for pediatric and geriatric populations can impede full-scale market penetration. Moreover, recurring ulceration is often a manifestation of underlying systemic issues such as gastrointestinal disorders or immunodeficiencies, thus demanding comprehensive healthcare strategies rather than standalone remedies. However, pharmaceutical R&D is focusing on dual-action formulations that combine anti-inflammatory and antimicrobial properties, which could redefine the therapeutic paradigm.
Pharmaceutical companies are also leaning into a hybrid model that emphasizes both prescription-strength formulations and consumer-accessible OTC products. The rising popularity of lozenges with anesthetic and healing agents reflects this blend of professional-grade efficiency and self-administered convenience. Additionally, ongoing clinical trials evaluating novel corticosteroid derivatives and antiseptic formulations for mucosal delivery indicate the next wave of therapeutic breakthroughs. Health-conscious consumers are also influencing trends toward sugar-free and preservative-free options in lozenges and gels.
Geographically, North America commands a dominant market share owing to a robust healthcare infrastructure, high awareness of oral hygiene, and widespread availability of advanced topical formulations. Europe follows closely with notable demand in countries like the UK, Germany, and France, where oral care innovation and insurance-backed prescription treatments have created strong market ecosystems. Meanwhile, Asia Pacific is emerging as the fastest-growing region, fueled by increasing population density, improving dental care access, and expanding retail pharmacy networks in countries such as India, China, and South Korea. Latin America and the Middle East & Africa are also expected to contribute meaningfully, supported by growing healthcare expenditure and oral health campaigns by government and non-governmental organizations.
Major market player included in this report are:
- GlaxoSmithKline plc
- Sun Pharmaceutical Industries Ltd.
- Colgate-Palmolive Company
- Pfizer Inc.
- 3M Company
- Bristol-Myers Squibb Company
- Reckitt Benckiser Group plc
- Church & Dwight Co., Inc.
- Bausch Health Companies Inc.
- ECR Pharmaceuticals
- Taro Pharmaceutical Industries Ltd.
- BLIS Technologies Ltd.
- Sinclair Pharma
- Prestige Consumer Healthcare Inc.
- Reddy's Laboratories Ltd.
The detailed segments and sub-segment of the market are explained below:
By Drug Class
- Antimicrobial
- Antihistamine
- Analgesics & Corticosteroids
By Formulation
By Region:
- North America
- U.S.
- Canada
- Europe
- UK
- Germany
- France
- Spain
- Italy
- Rest of Europe
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- Rest of Asia Pacific
- Latin America
- Brazil
- Mexico
- Rest of Latin America
- Middle East & Africa
- Saudi Arabia
- South Africa
- Rest of Middle East & Africa
Years considered for the study are as follows:
- Historical year - 2022
- Base year - 2023
- Forecast period - 2024 to 2032
Key Takeaways:
- Market Estimates & Forecast for 10 years from 2022 to 2032.
- Annualized revenues and regional level analysis for each market segment.
- Detailed analysis of geographical landscape with Country level analysis of major regions.
- Competitive landscape with information on major players in the market.
- Analysis of key business strategies and recommendations on future market approach.
- Analysis of competitive structure of the market.
- Demand side and supply side analysis of the market.
Table of Contents
Chapter 1. Global Mouth Ulcer Treatment Market Executive Summary
- 1.1. Global Mouth Ulcer Treatment Market Size & Forecast (2022-2032)
- 1.2. Regional Summary
- 1.3. Segmental Summary
- 1.3.1. By Drug Class
- 1.3.2. By Formulation
- 1.4. Key Trends
- 1.5. Recession Impact
- 1.6. Analyst Recommendation & Conclusion
Chapter 2. Global Mouth Ulcer Treatment Market Definition and Research Assumptions
- 2.1. Research Objective
- 2.2. Market Definition
- 2.3. Research Assumptions
- 2.3.1. Inclusion & Exclusion
- 2.3.2. Limitations
- 2.3.3. Supply Side Analysis
- 2.3.3.1. Availability
- 2.3.3.2. Infrastructure
- 2.3.3.3. Regulatory Environment
- 2.3.3.4. Market Competition
- 2.3.3.5. Economic Viability (Consumer's Perspective)
- 2.3.4. Demand Side Analysis
- 2.3.4.1. Regulatory Frameworks
- 2.3.4.2. Technological Advancements
- 2.3.4.3. Environmental Considerations
- 2.3.4.4. Consumer Awareness & Acceptance
- 2.4. Estimation Methodology
- 2.5. Years Considered for the Study
- 2.6. Currency Conversion Rates
Chapter 3. Global Mouth Ulcer Treatment Market Dynamics
- 3.1. Market Drivers
- 3.1.1. Rising incidence of recurrent aphthous stomatitis due to urban lifestyles and stress
- 3.1.2. Shift from generic OTC pain relievers to advanced, target-specific therapeutics
- 3.1.3. Growth of innovative delivery mechanisms (sustained-release gels and antiseptic lozenges)
- 3.2. Market Challenges
- 3.2.1. Variability in consumer preferences and regional cost barriers
- 3.2.2. Lack of specialized pediatric and geriatric formulations; need for comprehensive systemic care
- 3.3. Market Opportunities
- 3.3.1. Development of dual-action anti-inflammatory + antimicrobial formulations
- 3.3.2. Incorporation of natural ingredients (honey, aloe vera, licorice) in topical treatments
- 3.3.3. Expansion of digital platforms and tele-dentistry for early treatment uptake
Chapter 4. Global Mouth Ulcer Treatment Market Industry Analysis
- 4.1. Porter's Five Forces Model
- 4.1.1. Bargaining Power of Suppliers
- 4.1.2. Bargaining Power of Buyers
- 4.1.3. Threat of New Entrants
- 4.1.4. Threat of Substitutes
- 4.1.5. Competitive Rivalry
- 4.1.6. Futuristic Approach to Porter's Model
- 4.1.7. Porter's Five Forces Impact Analysis
- 4.2. PESTEL Analysis
- 4.2.1. Political
- 4.2.2. Economic
- 4.2.3. Social
- 4.2.4. Technological
- 4.2.5. Environmental
- 4.2.6. Legal
- 4.3. Top Investment Opportunities
- 4.4. Top Winning Strategies
- 4.5. Disruptive Trends
- 4.6. Industry Expert Perspectives
- 4.7. Analyst Recommendation & Conclusion
Chapter 5. Global Mouth Ulcer Treatment Market Size & Forecasts by Drug Class (2022-2032)
- 5.1. Segment Dashboard
- 5.2. Global Market: Antimicrobial Revenue Trend, 2022 & 2032 (USD Million)
- 5.3. Global Market: Antihistamine Revenue Trend, 2022 & 2032 (USD Million)
- 5.4. Global Market: Analgesics & Corticosteroids Revenue Trend, 2022 & 2032 (USD Million)
Chapter 6. Global Mouth Ulcer Treatment Market Size & Forecasts by Formulation (2022-2032)
- 6.1. Segment Dashboard
- 6.2. Global Market: Gels Revenue Trend, 2022 & 2032 (USD Million)
- 6.3. Global Market: Lozenges Revenue Trend, 2022 & 2032 (USD Million)
Chapter 7. Global Mouth Ulcer Treatment Market Size & Forecasts by Region (2022-2032)
- 7.1. North America Market
- 7.1.1. U.S. Market
- 7.1.1.1. By Drug Class (2022-2032)
- 7.1.1.2. By Formulation (2022-2032)
- 7.1.2. Canada Market
- 7.2. Europe Market
- 7.2.1. UK Market
- 7.2.2. Germany Market
- 7.2.3. France Market
- 7.2.4. Spain Market
- 7.2.5. Italy Market
- 7.2.6. Rest of Europe Market
- 7.3. Asia Pacific Market
- 7.3.1. China Market
- 7.3.2. India Market
- 7.3.3. Japan Market
- 7.3.4. Australia Market
- 7.3.5. South Korea Market
- 7.3.6. Rest of Asia Pacific Market
- 7.4. Latin America Market
- 7.4.1. Brazil Market
- 7.4.2. Mexico Market
- 7.4.3. Rest of Latin America Market
- 7.5. Middle East & Africa Market
- 7.5.1. Saudi Arabia Market
- 7.5.2. South Africa Market
- 7.5.3. Rest of Middle East & Africa Market
Chapter 8. Competitive Intelligence
- 8.1. Key Company SWOT Analysis
- 8.1.1. GlaxoSmithKline plc
- 8.1.2. Sun Pharmaceutical Industries Ltd.
- 8.1.3. Colgate-Palmolive Company
- 8.2. Top Market Strategies
- 8.3. Company Profiles
- 8.3.1. GlaxoSmithKline plc
- 8.3.1.1. Key Information
- 8.3.1.2. Overview
- 8.3.1.3. Financial (Subject to Data Availability)
- 8.3.1.4. Product Summary
- 8.3.1.5. Market Strategies
- 8.3.2. Sun Pharmaceutical Industries Ltd.
- 8.3.3. Colgate-Palmolive Company
- 8.3.4. Pfizer Inc.
- 8.3.5. 3M Company
- 8.3.6. Bristol-Myers Squibb Company
- 8.3.7. Reckitt Benckiser Group plc
- 8.3.8. Church & Dwight Co., Inc.
- 8.3.9. Bausch Health Companies Inc.
- 8.3.10. ECR Pharmaceuticals
- 8.3.11. Taro Pharmaceutical Industries Ltd.
- 8.3.12. BLIS Technologies Ltd.
- 8.3.13. Sinclair Pharma
- 8.3.14. Prestige Consumer Healthcare Inc.
- 8.3.15. Reddy's Laboratories Ltd.
Chapter 9. Research Process
- 9.1. Research Process
- 9.1.1. Data Mining
- 9.1.2. Analysis
- 9.1.3. Market Estimation
- 9.1.4. Validation
- 9.1.5. Publishing
- 9.2. Research Attributes
°ü·ÃÀÚ·á